



Porcine Virus and Vaccines

Guest Editors:

Dr. Huixing Lin

College of Veterinary Medicine,
Nanjing Agricultural University,
Nanjing, China

Dr. Chunfu Zheng

Department of Microbiology
Immunology and Infectious
Diseases, University of Calgary,
Calgary, AB, Canada

Deadline for manuscript
submissions:

25 October 2024

Message from the Guest Editors

Viruses may affect different systems of porcine, e.g., the gastrointestinal system, respiratory system, reproductive system, central nervous system, and heart, resulting in various porcine diseases. The virus causes serious losses to swine production every year, such as the African swine fever virus (ASFV), porcine epidemic diarrhea virus (PEDV), and porcine respiratory and reproductive dysfunction syndrome virus (PRRSV). It is an important measure for disease prevention to study the pathogenic mechanism of viruses and develop targeted vaccines. New immune adjuvants and optimization of administration routes may affect the immune effect of porcine vaccines. This Special Issue will gather the latest advances in porcine viruses and their vaccines.

Potential topics for this Special Issue include but are not limited to the following:

- Discovery and virulence identification of a new porcine virus;
- Immunosuppressive or pathogenic mechanism of a porcine virus;
- Development of a new porcine virus vaccine;
- Immunological assessment of a porcine vaccine;
- Immune adjuvants for a porcine vaccine;
- Optimization of administration route and/or formula in a porcine vaccine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com